NO312124B1 - Anvendelse av bisfosfonater for inhibering av benresorpsjon etter implantasjon av ortopediske proteser - Google Patents
Anvendelse av bisfosfonater for inhibering av benresorpsjon etter implantasjon av ortopediske proteser Download PDFInfo
- Publication number
- NO312124B1 NO312124B1 NO19964441A NO964441A NO312124B1 NO 312124 B1 NO312124 B1 NO 312124B1 NO 19964441 A NO19964441 A NO 19964441A NO 964441 A NO964441 A NO 964441A NO 312124 B1 NO312124 B1 NO 312124B1
- Authority
- NO
- Norway
- Prior art keywords
- bone
- bone resorption
- bisphosphonate
- orthopedic
- implant
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title claims abstract description 43
- 150000004663 bisphosphonates Chemical class 0.000 title claims abstract description 43
- 230000000399 orthopedic effect Effects 0.000 title claims abstract description 24
- 238000002513 implantation Methods 0.000 title description 4
- 230000030991 negative regulation of bone resorption Effects 0.000 title description 2
- 239000007943 implant Substances 0.000 claims abstract description 38
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940062527 alendronate Drugs 0.000 claims abstract description 20
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims abstract description 17
- 230000024279 bone resorption Effects 0.000 claims description 20
- 208000006386 Bone Resorption Diseases 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 9
- -1 BM 21 0995 Chemical compound 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 4
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 4
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 4
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002286 clodronic acid Drugs 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 229940009626 etidronate Drugs 0.000 claims description 4
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 4
- 229940046231 pamidronate Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229940089617 risedronate Drugs 0.000 claims description 4
- 229940019375 tiludronate Drugs 0.000 claims description 4
- RLIRIVMEKVNVQX-UHFFFAOYSA-L disodium;(2-cycloheptyl-1-phosphonatoethyl)-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)CC1CCCCCC1 RLIRIVMEKVNVQX-UHFFFAOYSA-L 0.000 claims description 3
- 238000004873 anchoring Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000006201 parenteral dosage form Substances 0.000 claims description 2
- 206010065687 Bone loss Diseases 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 description 43
- 238000000034 method Methods 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000011164 ossification Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000501 collagen implant Substances 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 208000037099 Prosthesis Failure Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- CEYUIFJWVHOCPP-UHFFFAOYSA-L disodium;(3-amino-1-hydroxy-1-phosphonatopropyl)phosphonic acid Chemical group [Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CEYUIFJWVHOCPP-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007941 heterotopic ossification Effects 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LZNFXJFOLTVFOP-UHFFFAOYSA-M sodium;hydroxy-(1-phosphono-2-pyridin-2-ylethyl)phosphinate Chemical compound [Na+].OP(O)(=O)C(P(O)([O-])=O)CC1=CC=CC=N1 LZNFXJFOLTVFOP-UHFFFAOYSA-M 0.000 description 1
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/230,670 US5646134A (en) | 1994-04-21 | 1994-04-21 | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| PCT/US1995/004498 WO1995028936A1 (en) | 1994-04-21 | 1995-04-17 | Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964441D0 NO964441D0 (no) | 1996-10-18 |
| NO964441L NO964441L (no) | 1996-10-18 |
| NO312124B1 true NO312124B1 (no) | 2002-03-25 |
Family
ID=22866129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964441A NO312124B1 (no) | 1994-04-21 | 1996-10-18 | Anvendelse av bisfosfonater for inhibering av benresorpsjon etter implantasjon av ortopediske proteser |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US5646134A (zh) |
| EP (2) | EP0756483B1 (zh) |
| JP (1) | JPH09512268A (zh) |
| CN (1) | CN1078073C (zh) |
| AT (1) | ATE236641T1 (zh) |
| AU (1) | AU2374895A (zh) |
| BG (1) | BG63102B1 (zh) |
| CA (1) | CA2188030C (zh) |
| CO (1) | CO4370025A1 (zh) |
| CZ (1) | CZ305596A3 (zh) |
| DE (1) | DE69530293T2 (zh) |
| DK (1) | DK0756483T3 (zh) |
| DZ (1) | DZ1873A1 (zh) |
| ES (1) | ES2194050T3 (zh) |
| FI (1) | FI964213A0 (zh) |
| HR (1) | HRP950239A2 (zh) |
| HU (1) | HUT74911A (zh) |
| IL (1) | IL113361A (zh) |
| MY (1) | MY114265A (zh) |
| NO (1) | NO312124B1 (zh) |
| NZ (1) | NZ284295A (zh) |
| PL (1) | PL318552A1 (zh) |
| PT (1) | PT756483E (zh) |
| RU (1) | RU2161032C2 (zh) |
| SK (1) | SK133396A3 (zh) |
| TW (1) | TW406021B (zh) |
| WO (1) | WO1995028936A1 (zh) |
| YU (1) | YU25295A (zh) |
| ZA (1) | ZA953185B (zh) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
| ES2197329T3 (es) * | 1996-02-14 | 2004-01-01 | Itzhak Binderman | Bisfosfonatos topicos para la prevencion de la reabsorcion osea. |
| US6117856A (en) * | 1996-02-14 | 2000-09-12 | Binderman; Itzhak | Topical bisphosphonates for prevention of bone resorption |
| US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6432932B1 (en) | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| SG109478A1 (en) * | 1997-07-22 | 2005-03-30 | Merck & Co Inc | Method for inhibiting bone resorption |
| IT1296495B1 (it) * | 1997-11-21 | 1999-06-25 | Prodotti Antibiotici Spa | Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare |
| US6414006B1 (en) | 1998-10-15 | 2002-07-02 | Merck Frosst Canada & Co. | Methods for inhibiting bone resorption |
| US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
| BR9915927A (pt) | 1998-12-04 | 2001-08-21 | Roche Diagnostics Gmbh | Uso de ácido ibandrÈnico ou seus sais ou ésteres fisiologicamente compatìveis |
| CA2356294C (en) | 1998-12-25 | 2007-06-05 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions for treating bone lesions in multiple myeloma |
| CA2370769A1 (en) * | 1999-04-22 | 2000-11-02 | Hydromed Sciences A Division Of Gp Strategies Corporation | Controlled delivery of bisphosphonates |
| AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
| AU781068B2 (en) * | 1999-08-19 | 2005-05-05 | Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The | Drug for treating fractures |
| WO2002004038A1 (en) * | 2000-07-12 | 2002-01-17 | Hopital Orthopedique De La Suisse Romande | Active biocoating for bone implant |
| CH694935A5 (de) * | 2000-07-26 | 2005-09-30 | Straumann Holding Ag | Oberflaechenmodifizierte Implantate. |
| AU2001221607A1 (en) * | 2000-11-20 | 2002-05-27 | Ecole Polytechnique Federale De Lausanne (Epfl) | Endosseous implant |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| SK9862003A3 (en) | 2001-02-06 | 2004-02-03 | Royal Alexandra Hosp Children | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| NZ528659A (en) * | 2001-04-03 | 2005-02-25 | Royal Alexandra Hosp Children | A drug for use in bone grafting |
| KR20020080018A (ko) * | 2001-04-10 | 2002-10-23 | 한국화학연구원 | 비스포스포네이트 골 흡수억제제의 이식형 서방성제제 |
| CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
| US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
| JP2005514400A (ja) * | 2001-12-21 | 2005-05-19 | ザ プロクター アンド ギャンブル カンパニー | 骨疾患の治療方法 |
| US7488496B2 (en) * | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
| US7491691B2 (en) * | 2002-05-03 | 2009-02-17 | Sindrey Dennis R | Connective tissue stimulating peptides |
| US20040137058A1 (en) * | 2002-07-09 | 2004-07-15 | Katdare Ashok V. | Effervescent bisphosphonate formulation |
| ES2561463T3 (es) * | 2003-08-21 | 2016-02-26 | Addbio Ab | Dispositivo de implante recubierto con bisfosfonato y método para el mismo |
| US20050181043A1 (en) * | 2004-02-12 | 2005-08-18 | Indranil Nandi | Alendronate salt tablet compositions |
| US7674454B2 (en) * | 2004-03-06 | 2010-03-09 | Innovata Limited | Enzyme-prodrug therapy for prosthetic joint repair |
| KR100564628B1 (ko) * | 2004-06-16 | 2006-03-28 | 삼성전자주식회사 | 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법 |
| US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| WO2006100527A1 (en) * | 2005-03-24 | 2006-09-28 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Effervescent tablet containing sodium alendronate and related use and process |
| US20070087052A1 (en) * | 2005-10-19 | 2007-04-19 | Katdare Ashok V | Effervescent bisphosphonate formulation |
| FR2904784B1 (fr) * | 2006-08-10 | 2010-09-03 | Surfactis Technologies | Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations |
| US20100144679A1 (en) * | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
| US8183225B2 (en) * | 2007-11-08 | 2012-05-22 | New York University | Inhibition of bone resorption using medical implants containing adenosine receptor antagonists |
| CN105920023A (zh) | 2009-09-01 | 2016-09-07 | 杜克大学 | 双膦酸类组合物及其治疗心力衰竭的方法 |
| US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
| KR20180115254A (ko) | 2010-12-06 | 2018-10-22 | 에프락스 파머슈티컬즈 소시에떼 아노님 | 신속한 용해 특성을 구비한 안정한 발포성 비스포스포네이트 제형 |
| US8858979B1 (en) | 2011-01-28 | 2014-10-14 | Clemson University | Service induced byproducts for localized drug delivery in orthopaedic implants |
| RU2661677C2 (ru) * | 2011-05-27 | 2018-07-18 | Аблинкс Нв | Ингибирование резорбции кости с помощью связывающих rank-l пептидов |
| EP2780021A4 (en) | 2011-11-16 | 2015-08-05 | Univ Duke | BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE |
| RU2653627C1 (ru) * | 2016-11-09 | 2018-05-11 | Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" | Способ моделирования асептического аминобисфосфонатного остеонекроза нижней челюсти у лабораторных белых крыс |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4446052A (en) * | 1982-05-17 | 1984-05-01 | The Procter & Gamble Company | Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate |
| US4753652A (en) * | 1984-05-04 | 1988-06-28 | Children's Medical Center Corporation | Biomaterial implants which resist calcification |
| CN1046853C (zh) * | 1988-01-20 | 1999-12-01 | 山之内制药株式会社 | 制备药用组合物的方法 |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| NZ253524A (en) * | 1992-05-29 | 1997-01-29 | Procter & Gamble Pharma | Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism) |
| AU5953894A (en) * | 1992-12-23 | 1994-07-19 | Merck & Co., Inc. | Bisphosphonate/estrogen therapy for treating and preventing bone loss |
| US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
| FI92465C (fi) * | 1993-04-14 | 1994-11-25 | Risto Tapani Lehtinen | Menetelmä endo-osteaalisten materiaalien käsittelemiseksi |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
-
1994
- 1994-04-21 US US08/230,670 patent/US5646134A/en not_active Expired - Lifetime
-
1995
- 1995-03-28 MY MYPI95000773A patent/MY114265A/en unknown
- 1995-03-30 TW TW084103056A patent/TW406021B/zh not_active IP Right Cessation
- 1995-04-13 IL IL11336195A patent/IL113361A/xx unknown
- 1995-04-17 PL PL95318552A patent/PL318552A1/xx unknown
- 1995-04-17 DK DK95916335T patent/DK0756483T3/da active
- 1995-04-17 AT AT95916335T patent/ATE236641T1/de not_active IP Right Cessation
- 1995-04-17 EP EP95916335A patent/EP0756483B1/en not_active Expired - Lifetime
- 1995-04-17 AU AU23748/95A patent/AU2374895A/en not_active Abandoned
- 1995-04-17 CA CA002188030A patent/CA2188030C/en not_active Expired - Fee Related
- 1995-04-17 ES ES95916335T patent/ES2194050T3/es not_active Expired - Lifetime
- 1995-04-17 DE DE69530293T patent/DE69530293T2/de not_active Expired - Fee Related
- 1995-04-17 PT PT95916335T patent/PT756483E/pt unknown
- 1995-04-17 HU HU9602888A patent/HUT74911A/hu unknown
- 1995-04-17 SK SK1333-96A patent/SK133396A3/sk unknown
- 1995-04-17 CZ CZ963055A patent/CZ305596A3/cs unknown
- 1995-04-17 JP JP7527678A patent/JPH09512268A/ja active Pending
- 1995-04-17 NZ NZ284295A patent/NZ284295A/en unknown
- 1995-04-17 WO PCT/US1995/004498 patent/WO1995028936A1/en active IP Right Grant
- 1995-04-17 CN CN95192675A patent/CN1078073C/zh not_active Expired - Fee Related
- 1995-04-17 EP EP01201914A patent/EP1197213A3/en not_active Withdrawn
- 1995-04-17 RU RU96121563/14A patent/RU2161032C2/ru not_active IP Right Cessation
- 1995-04-19 DZ DZ950041A patent/DZ1873A1/fr active
- 1995-04-19 CO CO95015985A patent/CO4370025A1/es unknown
- 1995-04-19 YU YU25295A patent/YU25295A/sh unknown
- 1995-04-20 ZA ZA953185A patent/ZA953185B/xx unknown
- 1995-04-20 HR HR08/230,670A patent/HRP950239A2/hr not_active Application Discontinuation
-
1996
- 1996-10-16 BG BG100910A patent/BG63102B1/bg unknown
- 1996-10-18 NO NO19964441A patent/NO312124B1/no not_active IP Right Cessation
- 1996-10-18 FI FI964213A patent/FI964213A0/fi unknown
-
1997
- 1997-06-16 US US08/876,898 patent/US5891863A/en not_active Expired - Fee Related
-
1998
- 1998-05-20 US US09/082,237 patent/US5972913A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0756483B1 (en) | Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis | |
| EP0635270B1 (en) | Parathyroid hormone and raloxifene for increasing bone mass | |
| US7612050B2 (en) | Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
| CA2151240A1 (en) | Biophosphonate/estrogen therapy for treating and preventing bone loss | |
| US5403829A (en) | Use of bisphosphonates in endo-osteal bone surgery | |
| EP0758241B1 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| US6399592B1 (en) | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss | |
| AU9745901A (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis | |
| AU2005203308A1 (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis | |
| RU2325170C1 (ru) | Биокомпозиционный материал для остеопластики | |
| AU3574799A (en) | Use of biphosphonates for inhibiting bone resorption following implantation of orthopedic prosthesis | |
| MXPA96004968A (en) | Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |